Rectal Cancer and Importance of Chemoradiation in the Treatment

  • Sergio Huerta
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 685)


Neoadjuvant chemoradiation is used as a preoperative standard treatment for the majority of patients with Stage II/III rectal cancers and, in attempt to facilitate surgical intervention, reduce the rate of local recurrence and improve overall outcomes in patients suffering from this malignancy. However, this modality results in a wide range of clinical responses. In many cases, a pathological complete response is achieved, while in others, receiving the same form of treatment, the tumor continues to grow. The specific phenotype of the tumor plays a major role in rendering tumor cells a survival advantage to the cytotoxic effects of chemoradiation. Several factors participating in proliferation, cell cycle, apoptosis and hypoxia have been investigated under a variety of conditions in pre-irradiated tissues and post-irradiated tumors. Mutations in the genes of these pathways have shown to lead to resistance to chemoradiation. This chapter describes colon cancer with emphasis on the molecular mechanisms that may lead to chemoradio-resistance of cells with cytotoxically induced DNA injury in rectal


Rectal Cancer Ionize Radiation Total Mesorectal Excision Radiat Oncol Biol Phys SW480 Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004; 13: 93–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Wong RK, Tandan V, De SS et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007: CD002102.Google Scholar
  3. 3.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Engstrom PF, Arnoletti JP, Benson AB, III et al. Rectal cancer. J Natl Compr Canc Netw 2007; 5: 940–981.PubMedGoogle Scholar
  5. 5.
    Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638–646.PubMedCrossRefGoogle Scholar
  6. 6.
    Nagtegaal ID, Marijnen CA, Kranenbarg EK et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26: 350–357.PubMedCrossRefGoogle Scholar
  7. 7.
    Mohiuddin M, Winter K, Mitchell E et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 2006; 24: 650–655.PubMedCrossRefGoogle Scholar
  8. 8.
    Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn 2009; 9: 469–480.PubMedCrossRefGoogle Scholar
  9. 9.
    Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Elshaikh M, Ljungman M, Ten HR et al. Advances in radiation oncology. Annu Rev Med 2006; 57: 19–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Lebe B, Sarioglu S, Sokmen S et al. The clinical significance of p53, p21 and p27 expressions in rectal carcinoma. Appl Immunohistochem Mol Morphol 2005; 13: 38–44.PubMedCrossRefGoogle Scholar
  12. 12.
    Willett CG, Warland G, Hagan MP et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995; 13: 1417–1424.PubMedGoogle Scholar
  13. 13.
    Willett CG, Warland G, Cheek R et al. Proliferating cell nuclear antigen and mitotic activity in rectal cancer: predictor of response to preoperative irradiation. J Clin Oncol 1994; 12: 679–682.PubMedGoogle Scholar
  14. 14.
    Rodel C, Grabenbauer GG, Papadopoulos T et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 2002; 52: 294–303.PubMedCrossRefGoogle Scholar
  15. 15.
    Lowe SW, Schmitt EM, Smith SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849.PubMedCrossRefGoogle Scholar
  16. 16.
    Bracey TS, Miller JC, Preece A et al. Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995; 10: 2391–2396.PubMedGoogle Scholar
  17. 17.
    Merritt AJ, Potten CS, Kemp CJ et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614–617.PubMedGoogle Scholar
  18. 18.
    Spitz FR, Nguyen D, Skibber JM et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665–1671.PubMedGoogle Scholar
  19. 19.
    Ribeiro JC, Barnetson AR, Fisher RJ et al. Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol 1997; 72: 11–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Vidaurreta M, Maestro ML, Sanz-Casla MT et al. Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int J Colorectal Dis 2008; 23: 581–586.PubMedCrossRefGoogle Scholar
  22. 22.
    Waldman T, Lengauer C, Kinzler KW et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713–716.PubMedCrossRefGoogle Scholar
  23. 23.
    Brugarolas J, Chandrasekaran C, Gordon JI et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552–557.PubMedCrossRefGoogle Scholar
  24. 24.
    Slebos RJ, Baas IO, Clement M et al. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br J Cancer 1996; 74: 165–171.PubMedCrossRefGoogle Scholar
  25. 25.
    Qiu H, Sirivongs P, Rothenberger M et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000; 43: 451–459.PubMedCrossRefGoogle Scholar
  26. 26.
    Palazzo JP, Kafka NJ, Grasso L et al. The role of p53, p21WAF1/C1PI and bcl-2 in radioresistant colorectal carcinoma. Hum Pathol 1997; 28: 1189–1195.PubMedCrossRefGoogle Scholar
  27. 27.
    Sogawa N, Takiguchi N, Koda K et al. Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol 2002; 21: 787–793.PubMedGoogle Scholar
  28. 28.
    Lin LC, Lee HH, Hwang WS et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006; 15: 211–216.PubMedCrossRefGoogle Scholar
  29. 29.
    Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000; 60: 679–684.PubMedGoogle Scholar
  30. 30.
    Waldman T, Zhang Y, Dillehay L et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3: 1034–1036.PubMedCrossRefGoogle Scholar
  31. 31.
    Moore HG, Shia J, Klimstra DS et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol 2004; 11: 955–961.PubMedCrossRefGoogle Scholar
  32. 32.
    Hoos A, Nissan A, Stojadinovic A et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 2002; 8: 3841–3849.PubMedGoogle Scholar
  33. 33.
    Huerta S, Goulet EJ, Huerta-Yepez S et al. Screening and detection of apoptosis. J Surg Res 2007; 139: 143–156.PubMedCrossRefGoogle Scholar
  34. 34.
    Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev Mol Diagn 2008; 8: 277–288.PubMedCrossRefGoogle Scholar
  35. 35.
    Meyn RE, Stephens LC, Milas L. Programmed cell death and radioresistance. Cancer Metastasis Rev 1996; 15: 119–131.PubMedCrossRefGoogle Scholar
  36. 36.
    Meyn RE, Stephens LC, Ang KK et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993; 64: 583–591.PubMedCrossRefGoogle Scholar
  37. 37.
    Schwandner O, Schiedeck TH, Bruch HP et al. Apoptosis in rectal cancer: prognostic significance in comparison with clinical histopathologic and immunohistochemical variables. Dis Colon Rectum 2000; 43: 1227–1236.PubMedCrossRefGoogle Scholar
  38. 38.
    [Anonymus]. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980–987.CrossRefGoogle Scholar
  39. 39.
    Marijnen CA, Nagtegaal ID, Mulder-Stapel AA et al. High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 2003; 57: 434–443.PubMedCrossRefGoogle Scholar
  40. 40.
    de Bruin EC, van de Velde CJ, van de Pas S et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 2006; 12: 6432–6436.PubMedCrossRefGoogle Scholar
  41. 41.
    Russo SM, Tepper JE, Baldwin AS, Jr. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183–193.PubMedCrossRefGoogle Scholar
  42. 42.
    Rodel C, Haas J, Groth A et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003; 55: 1341–1347.PubMedCrossRefGoogle Scholar
  43. 43.
    Rodel F, Hoffmann J, Grabenbauer GG et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002; 178: 426–435.PubMedCrossRefGoogle Scholar
  44. 44.
    Rodel F, Hoffmann J, Distel L et al. Survivin as a radioresistance factor and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881–4887.PubMedCrossRefGoogle Scholar
  45. 45.
    Rodel F, Frey B, Leitmann W et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008; 71: 247–255.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Sergio Huerta
    • 1
  1. 1.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations